RecruitingNCT06418412

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC

A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated Non-small Cell Lung Cancer (NSCLC)

Sponsor

National Cancer Centre, Singapore

Enrollment

600 participants

Start Date

Mar 15, 2024

Study Type

OBSERVATIONAL

Conditions

Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer

Summary

There are limited in depth studies on the epidemiology and clinical management of EGFR exon 20 insertion mutated NSCLC in Asia. In addition, there is preliminary data suggesting the exact location of the insertion and variant may influence the response and efficacy to novel EGFR targeted therapies. This study aims to fill this knowledge gap, by comprehensively characterising the epidemiology and clinical outcomes of Asian advanced EGFR exon 20 insertion mutated NSCLC patients.

Eligibility

Min Age: 21 YearsMax Age: 99 Years

Inclusion Criteria4

Histologically confirmed advanced NSCLC
Positive testing result from any locally approved test (including but not limited to RT-PCR, Cobas and NGS) for EGFR exon 20 insertion mutation
Diagnosis date from 1 Jan 2013 to 31 Dec 2024 (to allow for minimum 12 months of follow-up clinical and treatment outcome data)
Male or female adults, age as defined by local regulations

Exclusion Criteria1

\. Patients without an EGFR exon 20 insertion mutation

Locations(3)

National Cancer Centre, Singapore

Singapore, Singapore

Seoul National University Hospital

Seoul, South Korea

National Taiwan University Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06418412